Suit filed against Uber and others after allegedly suffering a violent attack at the hands of a hailed driver in downtown ...

Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. Insider talked to the leaders of five privately held biotechs for their views on IPOs in 2023.

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.